Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1980 4
1981 4
1982 2
1983 5
1984 2
1985 2
1986 2
1987 4
1988 6
1989 3
1990 4
1991 4
1992 2
1993 2
1994 3
1995 6
1996 5
1997 9
1998 3
2000 6
2001 4
2002 8
2003 4
2004 9
2005 6
2006 3
2007 4
2008 7
2009 1
2010 3
2011 7
2012 8
2013 4
2014 1
2015 3
2016 5
2017 6
2018 7
2019 9
2020 10
2021 5
2022 5
2023 6
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.
Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, Palevsky PM, Weisberg LS, Schorr CA, Trzeciak S, Walker PM; EUPHRATES Trial Investigators. Dellinger RP, et al. JAMA. 2018 Oct 9;320(14):1455-1463. doi: 10.1001/jama.2018.14618. JAMA. 2018. PMID: 30304428 Free PMC article. Clinical Trial.
IMPORTANCE: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may impr …
IMPORTANCE: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood wi …
Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis.
Terayama T, Yamakawa K, Umemura Y, Aihara M, Fujimi S. Terayama T, et al. Surg Infect (Larchmt). 2017 Apr;18(3):225-233. doi: 10.1089/sur.2016.168. Epub 2017 Jan 16. Surg Infect (Larchmt). 2017. PMID: 28092497 Review.
BACKGROUND: To evaluate the efficacy and safety of direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) therapy in patients with sepsis. DESIGN: A systematic review and meta-analysis of four major databases: Cochrane Central Register of Controlled Trial …
BACKGROUND: To evaluate the efficacy and safety of direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) therapy i …
Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial.
Liu S, Wu Y, Qi S, Shao H, Feng M, Xing L, Liu H, Gao Y, Zhu Z, Zhang S, Du Y, Lu Y, Yang J, Chen P, Sun T. Liu S, et al. Crit Care. 2023 Jun 13;27(1):232. doi: 10.1186/s13054-023-04522-6. Crit Care. 2023. PMID: 37312218 Free PMC article. Clinical Trial.
BACKGROUND: The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. ...TDM was employed to determine if the dose of …
BACKGROUND: The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the …
Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: A systematic review and meta-analysis.
Li X, Liu C, Mao Z, Qi S, Song R, Zhou F. Li X, et al. J Crit Care. 2021 Jun;63:187-195. doi: 10.1016/j.jcrc.2020.09.007. Epub 2020 Sep 18. J Crit Care. 2021. PMID: 33012579 Free article.
PURPOSE: To evaluate the efficacy and safety of Polymyxin B-immobilized hemoperfusion (PMX-HP) against sepsis or septic shock. METHODS: We searched databases (PubMed, EMBASE and Cochrane Library) to identify eligible randomized controlled trials (RCTs). ...
PURPOSE: To evaluate the efficacy and safety of Polymyxin B-immobilized hemoperfusion (PMX-HP) against sepsis or septic shock. …
Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence.
Falagas ME, Kyriakidou M, Voulgaris GL, Vokos F, Politi S, Kechagias KS. Falagas ME, et al. J Glob Antimicrob Resist. 2021 Mar;24:342-359. doi: 10.1016/j.jgar.2020.12.026. Epub 2021 Jan 21. J Glob Antimicrob Resist. 2021. PMID: 33486122 Free article. Review.
METHODS: We performed a review and meta-analysis to evaluate the current literature data regarding the effectiveness and safety of intravenous polymyxin B in patients with MDR Gram-negative bacterial infections and the overall mortality and nephrotoxicity in patient …
METHODS: We performed a review and meta-analysis to evaluate the current literature data regarding the effectiveness and safety of intraveno …
Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.
Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, Vincent JL, Pasero D, Robert R, Ronco C, Bagshaw SM. Fujii T, et al. Intensive Care Med. 2018 Feb;44(2):167-178. doi: 10.1007/s00134-017-5004-9. Epub 2017 Dec 4. Intensive Care Med. 2018. PMID: 29204670
PURPOSE: Polymyxin B-immobilized hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that clears circulating endotoxin. ...
PURPOSE: Polymyxin B-immobilized hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that clears circulat …
Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis.
Chang T, Tu YK, Lee CT, Chao A, Huang CH, Wang MJ, Yeh YC. Chang T, et al. Crit Care Med. 2017 Aug;45(8):e858-e864. doi: 10.1097/CCM.0000000000002362. Crit Care Med. 2017. PMID: 28445237 Free PMC article.
OBJECTIVE: Several studies have reported a survival benefit for polymyxin B hemoperfusion treatment in patients with severe sepsis and septic shock. However, recently, a propensity-matched analysis and a randomized controlled trial reported no survival benefit for …
OBJECTIVE: Several studies have reported a survival benefit for polymyxin B hemoperfusion treatment in patients with severe se …
Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial.
Osawa I, Goto T, Kudo D, Hayakawa M, Yamakawa K, Kushimoto S, Foster DM, Kellum JA, Doi K. Osawa I, et al. Crit Care. 2023 Jun 21;27(1):245. doi: 10.1186/s13054-023-04533-3. Crit Care. 2023. PMID: 37344804 Free PMC article. Clinical Trial.
BACKGROUND: Polymyxin B hemadsorption (PMX-HA) reduces blood endotoxin levels, but characteristics of patients with sepsis likely to benefit from PMX-HA are not well known. ...
BACKGROUND: Polymyxin B hemadsorption (PMX-HA) reduces blood endotoxin levels, but characteristics of patients with sepsis lik …
Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
Vardakas KZ, Falagas ME. Vardakas KZ, et al. Int J Antimicrob Agents. 2017 Feb;49(2):233-238. doi: 10.1016/j.ijantimicag.2016.07.023. Epub 2016 Sep 16. Int J Antimicrob Agents. 2017. PMID: 27686609 Review.
Colistin and polymyxin B (PMB) have different pharmacokinetic profiles and minor differences in antimicrobial activities that may result in discrepancies in mortality and nephrotoxicity. ...
Colistin and polymyxin B (PMB) have different pharmacokinetic profiles and minor differences in antimicrobial activities that …
Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials.
Chen JJ, Lai PC, Lee TH, Huang YT. Chen JJ, et al. Crit Care Med. 2023 Dec 1;51(12):1777-1789. doi: 10.1097/CCM.0000000000005991. Epub 2023 Jul 20. Crit Care Med. 2023. PMID: 37470680 Free PMC article.
Because of the presence of high clinical heterogeneity and intransitivity, the potential benefit of polymyxin-B hemoperfusion remained inconclusive. The analysis of secondary outcomes was limited by the scarcity of available studies. ...The therapeutic effect of …
Because of the presence of high clinical heterogeneity and intransitivity, the potential benefit of polymyxin-B hemoperfusion …
200 results

Searches related to "polymyxin b"